Three-year Outcomes of a Treat-and-Extend Regimen of Intravitreal Aflibercept for Wet ARMD at the Western Eye Hospital

Abstract

Wet age-related macular degeneration wARMD is the leading cause of central visual loss in elderly patients in the developed countries. Overexpression of vascular endothelial grown factor (VEGF) is known to play a major role in the pathogenesis of choroidal neovascularization. Aflibercept is a fully human, recombinant fusion protein that inhibits VEGF. It has a higher tendency to combine with VEGF-A and it blocks other factors such as VEGF-B and placental growth.